CY1114315T1 - Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα - Google Patents

Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Info

Publication number
CY1114315T1
CY1114315T1 CY20131100167T CY131100167T CY1114315T1 CY 1114315 T1 CY1114315 T1 CY 1114315T1 CY 20131100167 T CY20131100167 T CY 20131100167T CY 131100167 T CY131100167 T CY 131100167T CY 1114315 T1 CY1114315 T1 CY 1114315T1
Authority
CY
Cyprus
Prior art keywords
vaccination
excipients
limited
multiple dosage
dosage influenza
Prior art date
Application number
CY20131100167T
Other languages
English (en)
Inventor
Giudice Giuseppe Del
Riccardo Manetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114315(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1114315T1 publication Critical patent/CY1114315T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Εμβόλιο γρίπης χορηγείται με αγωγή πολλαπλών δόσεων, όπου (i) μία πρώτη δόση χορηγείται με ένα έκδοχο και (ii) μία μεταγενέστερη δόση χορηγείται είτε χωρίς έκδοχο ή με ένα διαφορετικό έκδοχο. Έτσι η εφεύρεση εξασφαλίζει τα πλεονεκτήματα μιας αγωγής δύο δόσεων χωρίς επίσης να διπλασιάζει την απαιτούμενη προμήθεια για ένα δεδομένο έκδοχο.
CY20131100167T 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα CY1114315T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81466506P 2006-06-15 2006-06-15
EP07804945A EP2032163B1 (en) 2006-06-15 2007-06-15 Adjuvant-sparing multi-dose influenza vaccination regimen

Publications (1)

Publication Number Publication Date
CY1114315T1 true CY1114315T1 (el) 2016-08-31

Family

ID=38832174

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100167T CY1114315T1 (el) 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Country Status (18)

Country Link
US (3) US20090220545A1 (el)
EP (1) EP2032163B1 (el)
JP (2) JP5566687B2 (el)
KR (1) KR20090016704A (el)
CN (1) CN101500603A (el)
AU (1) AU2007258874B2 (el)
BR (1) BRPI0713150A8 (el)
CA (1) CA2657989A1 (el)
CY (1) CY1114315T1 (el)
DK (1) DK2032163T3 (el)
EA (1) EA017441B1 (el)
ES (1) ES2401484T3 (el)
HK (1) HK1129205A1 (el)
PL (1) PL2032163T3 (el)
PT (1) PT2032163E (el)
SI (1) SI2032163T1 (el)
WO (1) WO2007144772A2 (el)
ZA (1) ZA200810582B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2268309B1 (en) * 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR101176305B1 (ko) * 2009-10-14 2012-08-23 웅진코웨이주식회사 붉나무 추출물을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
PT2525815E (pt) * 2010-01-24 2015-03-05 Novartis Ag Micropartículas de polímero biodegradável irradiadas
US8852157B2 (en) 2010-02-21 2014-10-07 Innovative Bottles, Llc Disposable items made from bioplastic resins
CN102232042B (zh) * 2010-02-21 2015-01-14 创新瓶业有限责任公司 生物可降解药房容器以及安全盖
US20130064852A1 (en) * 2010-05-11 2013-03-14 Intervet International B.V. Vaccine against mycoplasma, hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
JP2017528430A (ja) 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
TWI741969B (zh) * 2014-10-30 2021-10-11 日商中外製藥股份有限公司 具備注射器蓋之附針預填充注射器製劑
MX2017009380A (es) 2015-02-03 2018-01-09 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY
JP2021533157A (ja) * 2018-08-07 2021-12-02 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
WO1990001947A1 (en) 1988-08-25 1990-03-08 The Liposome Company, Inc. Affinity associated vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
PL1635863T3 (pl) * 2003-06-17 2011-01-31 Mannkind Corp Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
HUE027837T2 (en) * 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response
US20100158943A1 (en) * 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.

Also Published As

Publication number Publication date
DK2032163T3 (da) 2013-03-25
PL2032163T3 (pl) 2013-06-28
AU2007258874A1 (en) 2007-12-21
ES2401484T3 (es) 2013-04-22
US20140370053A1 (en) 2014-12-18
US20120039934A1 (en) 2012-02-16
WO2007144772A3 (en) 2008-03-27
US20090220545A1 (en) 2009-09-03
KR20090016704A (ko) 2009-02-17
CN101500603A (zh) 2009-08-05
EP2032163A2 (en) 2009-03-11
EP2032163B1 (en) 2013-01-23
PT2032163E (pt) 2013-04-11
AU2007258874B2 (en) 2013-11-14
JP5566687B2 (ja) 2014-08-06
BRPI0713150A2 (pt) 2012-03-27
JP2009539965A (ja) 2009-11-19
CA2657989A1 (en) 2007-12-21
EA017441B1 (ru) 2012-12-28
EA200970013A1 (ru) 2009-06-30
HK1129205A1 (en) 2009-11-20
JP5981951B2 (ja) 2016-08-31
JP2014098038A (ja) 2014-05-29
SI2032163T1 (sl) 2013-05-31
WO2007144772A2 (en) 2007-12-21
US9901630B2 (en) 2018-02-27
ZA200810582B (en) 2009-09-30
US8808686B2 (en) 2014-08-19
BRPI0713150A8 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
CY1114315T1 (el) Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
CY1120347T1 (el) Εμβολιο ιου ερπητα ζωστηρα
NZ585674A (en) Vaccination with multiple clades of h5 influenza a virus
CY1111553T1 (el) Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CL2021003017S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
WO2008096831A1 (ja) 癌の治療剤
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
NO20065480L (no) Vaksiner.
BRPI0716518B8 (pt) vacina de ipv e uso da mesma
CR11307A (es) Vacunas
DE60142615D1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
AR121361A1 (es) Vacuna
PH12019500330A1 (en) Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
CY1107302T1 (el) Χρηση ρεσβερατρολης για την παρασκευη ενος φαρμακου που ειναι χρησιμο για τη θεραπεια λοιμωξεων απο τον ιο της γριπης
CR11575A (es) Vacuna
AR052392A1 (es) Mutantes de la proteina n del virus del sindrome reproductor y respiratorio de los porcinos
AR119159A1 (es) Tratamientos de angioedema
BRPI0606165A2 (pt) método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
BR112022000710A2 (pt) Vacina viral terapêutica